Checkmate Pharmaceuticals Presents Clinical Trial Biomarker Data with Vidutolimod at the 2022 American Association for Cancer Research (AACR) Annual Meeting
08 Avril 2022 - 7:01PM
Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI)
(“Checkmate”), a clinical stage biotechnology company focused
on developing its proprietary technology to harness the power of
the immune system to combat cancer, today announced the
presentation of biomarker signature data from two studies
evaluating vidutolimod, a first-in-class, immunostimulatory,
noninfectious virus-like particle (VLP) containing a CpG-A
Toll-like receptor 9 (TLR9) agonist. The first study evaluated
vidutolimod in patients with advanced anti-PD-(L)1 refractory
melanoma who received intratumoral vidutolimod monotherapy or in
combination with intravenous pembrolizumab, and the second
evaluated patients with anti-PD-(L)1 refractory non-small cell lung
cancer (NSCLC) who received vidutolimod and atezolizumab. The
objective of these analyses was to identify transcriptional
signatures specific to the antitumor activity of treatment with
vidutolimod monotherapy or in combination with PD-1 blockade in
these two subsets.
Novel transcriptional signatures associated
with antitumor activity in vidutolimod (vidu)-treated patients
(pts) with anti-PD-1-refractory melanoma and non-small cell lung
cancer (NSCLC) (Abstract #: LB107: NCT03084640 and
NCT03438318)
During the 2022 AACR Late-Breaking Research: Clinical Research 2
Poster Session on Tuesday, April 12 from 9:00am - 12:30pm CT, Art
Krieg, M.D., Founder and Chief Scientific Officer of Checkmate,
presents analyses of RNA Seq data from baseline biopsies of tumors
in patients with anti-PD-1-refractory melanoma and NSCLC.
Key highlights from these clinical trial biomarker data
include:
- Expression of a 35-gene COPII/Golgi core signature was
associated with antitumor activity of intratumoral vidutolimod ±
intravenous anti–PD-(L)1. This finding is consistent with published
reports that COPII vesicle and Golgi trafficking are critical for
TLR9 trafficking and function
- Association with response to vidutolimod monotherapy suggests
that the COPII/Golgi core signature is linked to effective TLR9
agonism. The signature was independent of tumor inflammation and
baseline patient characteristics such as LDH, presence of liver
metastases, or tumor burden
- Machine learning of the RNA Seq dataset revealed that the
COPII/Golgi signature in combination with ELF2 expression provided
a stronger differentiation between responders and non-responders to
vidutolimod, regardless of baseline tumor inflammation
- A macrophage signature was associated with nonresponse in T
cell–inflamed melanoma, consistent with other evidence that high
concentrations of tumor-associated macrophages (or myeloid-derived
suppressor cells) may suppress TLR9 activation by vidutolimod
- The presence of these signatures and potential association with
clinical response is being evaluated in further RNA Seq datasets
being generated from ongoing clinical trials of vidutolimod in
combination with various checkpoint inhibitors
“These data suggest that the tumor regression we have seen in
patients treated with intratumoral vidutolimod with or without
checkpoint inhibitors may be predicted from the presence of one or
more novel transcriptional signatures in the baseline tumor
biopsies,” said Dr. Art Krieg, Founder and Chief Scientific Officer
of Checkmate. “These signatures are consistent with what we know
about TLR9 biology and they provide clues to possible new
combinations and patient populations who may be especially amenable
to vidutolimod treatment. We look forward to determining the
prevalence of these signatures in other cancers and to exploring
the potential for a biomarker-based enrichment strategy across
cancer.”
About Checkmate Pharmaceuticals
Checkmate Pharmaceuticals is a clinical stage biotechnology
company focused on developing its proprietary technology to harness
the power of the immune system to combat cancer. Checkmate
Pharmaceuticals’ product candidate, vidutolimod (CMP-001), is an
advanced generation Toll-like receptor 9 (TLR9) agonist, delivered
as a biologic virus-like particle utilizing a CpG-A
oligodeoxynucleotide as a key component, designed to trigger the
body’s innate immune system to attack tumors in combination with
other therapies. Information regarding Checkmate Pharmaceuticals is
available at www.checkmatepharma.com.
Availability of Other Information About Checkmate
Pharmaceuticals
Investors and others should note that we communicate with our
investors and the public using our website
(www.checkmatepharma.com) and our investor relations website
(ir.checkmatepharma.com), including but not limited to: investor
presentations and investor fact sheets, U.S. Securities and
Exchange Commission filings, press releases, public conference
calls and webcasts. The information that Checkmate Pharmaceuticals
posts on these channels and websites could be deemed to be material
information. As a result, we encourage investors, the media, and
others interested in us to review the information that is posted on
these channels, including the investor relations website, on a
regular basis. The contents of our website or these channels, or
any other website that may be accessed from our website or these
channels, shall not be deemed incorporated by reference in any
filing under the Securities Act of 1933.
Forward-Looking Statements
Various statements in this release are “forward-looking
statements” within the meaning of the Private Securities Litigation
Reform Act of 1995, as amended, including words such as, but not
limited to, “anticipate,” “believe,” “can,” “could,” “expect,”
“estimate,” “design,” “goal,” “intend,” “may,” “might,”
“objective,” “plan,” “predict,” “project,” “target,” “likely,”
“should,” “will,” and “would,” or the negative of these terms and
similar expressions or words, identify forward-looking statements.
Forward-looking statements are based upon current expectations that
involve risks, changes in circumstances, assumptions, and
uncertainties. These statements include those regarding vidutolimod
(CMP-001), including its development, efficacy and therapeutic
potential and the advancement of our clinical and preclinical
pipeline, the ability to expand into new cancer indications, the
timing of potential data read outs on our ongoing clinical trials,
our anticipated cash runway, and our ability to raise additional
capital to fund our clinical development program and continue as a
going concern. Forward-looking statements should not be read as a
guarantee of future performance or results and may not be accurate
indications of when such performance or results will be achieved.
These forward-looking statements are subject to risks and
uncertainties, including those related to the development of
vidutolimod, including any delays in our ongoing or planned
preclinical or clinical trials, the results from clinical trials,
including the fact that positive results from a trial may not
necessarily be predictive of the results of future or ongoing
clinical trials, the impact of the ongoing COVID-19 pandemic on our
business, operations, clinical supply , clinical enrollment and
plans, the risks inherent in the drug development process,
including related to regulatory approval, the risks regarding the
accuracy of our estimates of expenses and timing of development,
our capital requirements, the need for additional financing and the
ability to obtain financing, and obtaining, maintaining and
protecting our intellectual property. These and additional risks
are discussed in the sections titled “Risk Factors” and
“Management’s Discussion and Analysis of Financial Condition and
Results of Operations” in our Annual Report on Form 10-K for the
year ending December 31, 2021, as filed with the Securities and
Exchange Commission which are available on the Securities and
Exchange Commission’s website at www.sec.gov, and as well as
discussions of potential risks, uncertainties and other important
factors in our subsequent filings with the Securities and Exchange
Commission. All information in this press release is as of the date
of the release, and Checkmate undertakes no duty to update this
information unless required by law.
Investor Contact
Rob Dolski
Chief Financial Officer
rdolski@checkmatepharma.com
Media Contact
Karen Sharma
MacDougall Advisors
781-235-3060
ksharma@macdougall.bio
Checkmate Pharmaceuticals (NASDAQ:CMPI)
Graphique Historique de l'Action
De Sept 2024 à Oct 2024
Checkmate Pharmaceuticals (NASDAQ:CMPI)
Graphique Historique de l'Action
De Oct 2023 à Oct 2024